Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667807 | 1.00 | ALDH1A1 (0.45) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL21667806 | 1.00 | ALDH1A1 (0.45) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL21941259 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL21941319 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL21941321 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL22509522 | 0.81 | ALDH1A1 (0.39) | ALDH1A1KDM4ECXCR4 | |
| SCHEMBL24428771 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL25609756 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL21667838 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL25609759 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4ECXCR4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | ALDH1A1 430/4885KDM4E 502/4885CXCR4 4183/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | ALDH1A1 430/4885KDM4E 502/4885CXCR4 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.